Skip to main content
HCPCS A9579 · Level II · Part B drug

A9579: gadolinium-based magnetic resonance contrast agent (Prohance, Omniscan, Ambelvist), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for A9579

Billing unit
1 ML
Gad-base mr contrast nos,1ml
ASP payment limit
$1.435
October 2026; +0.0% vs July 2026
Practitioner MUE
100
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS A9579 is the Level II code for Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml, billed per 1 ML. The Medicare Part B ASP payment limit for October 2026 is $1.435 per billing unit, up 0.0% from July 2026. The practitioner MUE allows up to 100 units per date of service (MAI 3), so a full 100-unit day is $143.50 at the current limit. Under OPPS it carries status indicator N. Diagnostic agents are usually packaged under OPPS (status N) in the hospital outpatient setting, so separate payment applies mainly in the physician office under Part B. The ASP crosswalk maps 18 NDCs to it, sold as Prohance, Omniscan, Ambelvist by Bracco Diagnostics Inc., GE Healthcare Inc., Bayer HealthCare Pharmaceuticals Inc. No current Billing and Coding Article lists A9579, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for A9579 at $1.435 per 1 ML for October 2026, derived from manufacturer average sales price plus 6%, compared with $1.435 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for A9579
QuarterPayment limitPerCoinsurance
October 2026$1.4351 ML20%
July 2026$1.4351 ML—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 18 NDCs from 4 labelers to A9579. Report the NDC in the claim's drug segment and bill the number of A9579 units that equals the quantity administered divided by 1 ML; the last column gives units per full package.

NDCs that crosswalk to A9579
NDCDrug nameLabelerPackage sizeBilling units / package
00270-1111-01ProhanceBracco Diagnostics Inc.10 × 550
00270-1111-02ProhanceBracco Diagnostics Inc.15 × 575
00270-1111-03ProhanceBracco Diagnostics Inc.20 × 5100
00270-1111-04ProhanceBracco Diagnostics Inc.5 × 525
00270-1111-85ProhanceBracco Diagnostics Inc.100 × 5500
00407-0690-05OmniscanGE Healthcare Inc.5 × 1050
00407-0690-10OmniscanGE Healthcare Inc.10 × 10100
00407-0690-12OmniscanGE Healthcare Inc.10 × 10100
00407-0690-15OmniscanGE Healthcare Inc.15 × 10150
00407-0690-17OmniscanGE Healthcare Inc.15 × 10150
00407-0690-20OmniscanGE Healthcare Inc.20 × 10200
00407-0690-22OmniscanGE Healthcare Inc.20 × 10200
00407-0690-70OmniscanGE Healthcare Inc.100 × 101000
50419-0323-11AmbelvistBayer HealthCare Pharmaceuticals Inc.10 × 10100
70436-0121-31GadoteridolSlate Run Pharmaceuticals5 × 525
70436-0121-33GadoteridolSlate Run Pharmaceuticals10 × 550
70436-0121-34GadoteridolSlate Run Pharmaceuticals15 × 575
70436-0121-35GadoteridolSlate Run Pharmaceuticals20 × 5100

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for A9579. For practitioners the limit is 100 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for A9579 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1003 Date of Service Edit: ClinicalPrescribing Information

MUE for A9579 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists A9579 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check A9579 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

A9579 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists A9579 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, A9579 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), A9579 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for A9579 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for A9579

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS A9579

What does HCPCS code A9579 describe?

A9579 is defined by CMS as "Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml". Each billing unit represents 1 ML, so the units reported on the claim must equal the dose administered divided by that unit.

Is A9579 a CPT code?

No. A9579 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as gadolinium-based magnetic resonance contrast agent; CPT codes are five-character codes maintained by the AMA. On a Part B claim A9579 reports the drug itself in 1 ml units, and the administration is billed on its own line.

What is the Medicare reimbursement for A9579 in October 2026?

The ASP-based payment limit is $1.435 per 1 ML, with 20% beneficiary coinsurance. The July 2026 limit was $1.435. Commercial payers use their own fee schedules.

How many units of A9579 can be billed per day?

The practitioner Medically Unlikely Edit is 100 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to A9579?

The October 2026 ASP crosswalk lists 18 NDCs from 4 labelers: Prohance (Bracco Diagnostics Inc.); Omniscan (GE Healthcare Inc.); Ambelvist (Bayer HealthCare Pharmaceuticals Inc.); Gadoteridol (Slate Run Pharmaceuticals). For example NDC 00270-1111-01 (package size 10) equals 50 billing units of A9579.

Does A9579 have NCCI bundling edits?

No active practitioner PTP pairs list A9579 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.